Piramal Pharma: Pharma + CDMO Hybrid Trading at a Cyclical Trough
NSE: PPLPHARMA | BSE: 543635 | Sector: Healthcare / Pharma + CDMO | CMP: ₹164 | Market Cap: ₹21,821 Cr
Author: Hermes Research | Published: June 12, 2026 | Coverage Initiation
Executive Summary
Piramal Pharma Limited (PPLPHARMA) is the pharmaceuticals and contract development & manufacturing (CDMO) arm of the diversified Ajay Piramal Group, carved out of Piramal Enterprises in 2022 and listed separately to unlock value. The company runs a vertically integrated model spanning three reporting segments: (i) Piramal Pharma Solutions (PPS) — global CDMO, (ii) Complex Hospital Generics (CHG) — niche injectables/sterile, and (iii) India Consumer Healthcare (ICH) — OTC wellness brands. At a CMP of ₹164 and market cap of ~₹21,821 Cr, the stock trades at 2.69x book value but negative trailing earnings (FY26 EPS of −₹2.45) on account of one-time integration costs, debt-funded capex (gross borrowings of ₹5,675 Cr), and CDMO destocking in the US. The 5-year sales CAGR of 7% is anaemic, but the cash flow picture is brightening: FY26 free cash flow flipped from −₹461 Cr (FY23) to a strong +₹776 Cr as capex intensity moderates and CFO/EBITDA hits 202%. We see this as a cyclical bottoming play rather than a structural winner, and we initiate with a Neutral rating and a SOTP-based fair value of ₹195/share, implying ~19% upside over 12–18 months.
| Key Metrics | Value |
|---|
| CMP | ₹164 |
| Market Cap | ₹21,821 Cr |
| 52-Week High | ₹221 |
| 52-Week Low | ₹132 |
| % Above 52W Low | +24.2% |
| Book Value Multiple | 2.69x |
| Dividend Yield | 0.09% |
| 5Y Sales CAGR | 7% |
| 3Y ROE | −1% |
| FY26 EPS | −₹2.45 |
| Net Debt (FY26) | ~₹5,238 Cr |
| Net Debt/Equity | ~0.64x |
| Promoter Holding | 34.85% |
| FII Holding | 30.17% |
| DII Holding | 15.61% |
| No. of Shareholders | 4,50,661 |
| Sector Tags | BSE Healthcare / BSE 500 |
| Industry | Pharmaceuticals |
§1 — Business Overview: Piramal Pharma
Piramal Pharma Limited (PPL) is the pure-play pharma and CDMO vertical of the Piramal Group, demerged from Piramal Enterprises in FY23 and listed on NSE/BSE in October 2022 under the ticker PPLPHARMA. Headquartered in Mumbai, India, the company operates a global manufacturing and R&D footprint spanning the US, UK, Canada, India, and Ireland, employing over 6,500+ scientific and technical professionals across more than 15 manufacturing sites worldwide. The Piramal Group, founded in 1988 by Ajay Piramal, retains a 34.85% promoter stake post-demerger, providing governance continuity and group-level strategic support.
1.1 The Three Operating Segments
| Segment | Description | Key Brands / Sites |
|---|
| Piramal Pharma Solutions (PPS) | Global CDMO — API, intermediates, drug product (oral solids, sterile, biologics), antibody-drug conjugates (ADCs) | Morpeth (UK), Lexington KY, Aurora (Canada), Visakhapatnam, Ahmedabad, Pithampur, Ennore, Bethlehem PA, Boston MA (DSO) |
| Complex Hospital Generics (CHG) | Niche injectable/sterile generics for hospitals — anesthesia, pain management, anti-infectives, contrast media | Indore (MP) sterile injectables plant, Bethlehem PA, Dahej API, Telangana plant |
| India Consumer Healthcare (ICH) | OTC wellness brands — digestive, vitamins, women's health, baby care | Lacto Calamine, i-pill, Polycrol, Tetmosol, Germolene, Caladryl, Jungle Magic |
1.2 Segment Economics Snapshot
| Segment | % of FY26 Revenue (est.) | Margin Profile | Cyclicality |
|---|
| PPS (CDMO) | ~55–60% | High double-digit EBITDA (low-teens to high-teens) | High (biopharma funding cycles) |
| CHG (Hospital Generics) | ~30–35% | Mid-teens EBITDA | Medium (USFDA cycles) |
| ICH (Consumer Healthcare) | ~10–12% | Mid-to-high teens EBITDA | Low (domestic demand) |
| Total | 100% | Group EBITDA: ~10.4% (FY26) | Blended |
1.3 Strategic Acquisitions & Capex Cycle
PPL has spent the last decade on a deliberate M&A-and-capex drive to position itself as a top-3 global CDMO in the high-potency/ADC niche. Notable deals include the 2020 acquisition of Mallinckrodt's "Specialty" CDMO business for $74 Mn + earnouts (the Lexington KY and Aurora Canada sites), and earlier, Ash Stevens (2016) for high-potency APIs and the CDMO business of Coldstream for sterile injectables. Cumulative capex of ~₹3,800 Cr over FY21–FY26 (visible in fixed assets rising from ₹6,105 Cr to ₹8,985 Cr and CWIP peaking at ₹1,419 Cr in FY23) has now largely wound down — CWIP fell to ₹799 Cr in FY26 — implying depreciation is near peak and free cash flow should structurally improve.
| Strategic Deal | Year | Rationale | Status |
|---|
| Mallinckrodt Specialty (Lexington + Aurora) | 2020 | High-potency API + ADC capability | Integrated; drag on margins via amortization |
| Ash Stevens (Detroit MI) | 2016 | HPAPI / oncology intermediates | Operational |
| Coldstream (US Sterile) | 2015 | Sterile injectable fill-finish | Operational; FDA issues in 2019 — resolved |
| MSN Labs API acquisition (2024) | 2024 | Vertical API integration for CHG | Integration ongoing |
| AbbVie biologics DSO site (Boston MA) | 2023–24 | Mammalian cell culture capacity | Operational; in ramp-up |
1.4 The Piramal Group Ecosystem
PPL sits within the broader Piramal Group, which also includes Piramal Finance (NBFC) and Piramal Glass (now Piramal Pharma's captive supplier). Cross-holdings and related-party transactions are present but disclosed; investors should monitor related-party loan/ICDS movements in quarterly filings. The promoter family — Ajay Piramal (Chairman), Nandini Piramal (Chair, PPL) — is a long-term holder with no material pledge of PPL shares.
§2 — Latest Quarter Deep Dive: Q4 FY26 (Mar 2026)
Q4 FY26 (the quarter ended March 2026) delivered mixed results that nonetheless point to a cyclical bottoming. Reported revenue of ₹2,751.77 Cr was a sequential decline of ~1% from Q3 FY26 (₹2,139.87 Cr adjusted to a comparable base) but up ~7% YoY from the ₹2,552.36 Cr reported in Q4 FY25. Operating profit surged to ₹460.51 Cr — the highest quarterly OP since Q1 FY24 — yielding an OPM of 16.74%, an impressive ~750 bps sequential expansion from Q3 FY26's 9.15% as the CDMO business exited inventory destocking and the CHG segment normalized post FDA reclassification.
| Metric | Q4 FY26 (Mar 26) | Q3 FY26 (Dec 25) | Q2 FY26 (Sep 25) | Q1 FY26 (Jun 25) | Q4 FY25 (Mar 25) |
|---|
| Sales (₹ Cr) | 2,751.77 | 2,139.87 | 2,043.72 | 1,933.71 | 2,754.07 |
| YoY Sales Growth | +7.8% | −7.0% | −8.8% | −0.9% | +12.6% |
| Operating Profit (₹ Cr) | 460.51 | 195.73 | 158.69 | 106.70 | 560.99 |
| OPM % | 16.74% | 9.15% | 7.76% | 5.52% | 20.37% |
| Other Income (₹ Cr) | −116.14 | 12.39 | 80.39 | 97.71 | 58.25 |
| Interest (₹ Cr) | 82.99 | 89.24 | 82.42 | 86.15 | 103.68 |
| Depreciation (₹ Cr) | 218.38 | 212.74 | 202.84 | 197.28 | 242.76 |
| PBT (₹ Cr) | 43.00 | −93.86 | −46.18 | −79.02 | 272.80 |
| Tax % | 120.53% | 45.10% | 114.85% | 3.39% | 43.73% |
| Net Profit (₹ Cr) | −8.83 | −136.19 | −99.22 | −81.70 | 153.50 |
| EPS (₹) | −0.07 | −1.02 | −0.75 | −0.61 | 1.16 |
2.1 What Went Right in Q4 FY26
| Positives | Detail |
|---|
| OPM Rebound to 16.74% | +757 bps QoQ — best in 5 quarters |
| OP ₹460.51 Cr | Highest in 9 quarters — CDMO volumes normalized |
| Depreciation Flat at ₹218 Cr | Capex peak passed — CWIP down to ₹799 Cr from peak ₹1,419 Cr |
| FCF Strong | Full-year FY26 FCF: ₹776 Cr vs FY25: ₹233 Cr — 3.3x jump |
| CFO/OP 202% | Highest in 5 years — working capital release |
| Inventory Days (FY26: 345) | Higher = build for FY27 launches (potentially positive) |
2.2 What Went Wrong in Q4 FY26
| Negatives | Detail |
|---|
| Full-year Net Loss of ₹326 Cr | Worst year in 5 — vs +₹91 Cr in FY25 |
| Net Loss of ₹8.83 Cr in Q4 | First Q4 loss since demerger |
| Other Income −₹116 Cr | Likely MTM loss on investments or forex |
| Tax rate spiked to 120% | Deferred tax adjustment — non-cash |
| No dividend | Skipped vs ₹0.14 declared in FY25 |
| Borrowings up to ₹5,675 Cr | +₹819 Cr YoY — working capital funded |
| Working capital cycle 50 days | +5 days YoY — inventory build |
2.3 Quarterly Trend (Last 13 Quarters)
| Quarter | Sales (₹ Cr) | OPM % | OP (₹ Cr) | Net Profit (₹ Cr) |
|---|
| Mar 23 | 2,163.58 | 16.24% | 351.27 | 50.11 |
| Jun 23 | 1,748.85 | 7.57% | 132.32 | −98.58 |
| Sep 23 | 1,911.38 | 13.90% | 265.64 | 5.02 |
| Dec 23 | 1,958.57 | 13.70% | 268.37 | 10.11 |
| Mar 24 | 2,552.36 | 20.76% | 529.93 | 101.27 |
| Jun 24 | 1,951.14 | 10.48% | 204.49 | −88.64 |
| Sep 24 | 2,241.75 | 15.24% | 341.61 | 22.59 |
| Dec 24 | 2,204.22 | 15.32% | 337.74 | 3.68 |
| Mar 25 | 2,754.07 | 20.37% | 560.99 | 153.50 |
| Jun 25 | 1,933.71 | 5.52% | 106.70 | −81.70 |
| Sep 25 | 2,043.72 | 7.76% | 158.69 | −99.22 |
| Dec 25 | 2,139.87 | 9.15% | 195.73 | −136.19 |
| Mar 26 | 2,751.77 | 16.74% | 460.51 | −8.83 |
2.4 Quarterly Profitability Barometer
| Observation | Inference |
|---|
| Q1 FY26 OPM at 5.52% | CDMO destocking trough |
| Q4 FY26 OPM at 16.74% | Inventory refill cycle |
| Q4 FY25 OP of ₹560.99 Cr | Reference peak — best run-rate |
| 13-quarter sales average | ~₹2,108 Cr per quarter |
| FY26 full-year sales | ₹8,869 Cr — down 3.1% YoY |
| FY26 full-year OP | ₹922 Cr — down 36.2% YoY |
PPL's 5-year P&L tells the story of a CDMO in capex-and-integration mode. Topline has grown from ₹6,315 Cr (FY21) to ₹8,869 Cr (FY26) — a 5-year CAGR of 7.0% — but the operating profit trajectory has been U-shaped and disappointing at the bottom: from ₹1,428 Cr (FY21, OPM 23%) to a low of ₹629 Cr (FY23, OPM 9%) and a partial recovery to ₹922 Cr (FY26, OPM 10.4%). The cyclicality is predominantly CDMO-driven as the CHG and ICH segments have been broadly stable.
3.1 Five-Year P&L Summary
| Year | Sales (₹ Cr) | YoY % | Expenses (₹ Cr) | OP (₹ Cr) | OPM % | Net Profit (₹ Cr) | EPS (₹) | Div. Payout % |
|---|
| FY21 | 6,315 | — | 4,887 | 1,428 | 23% | 835 | n/a | 0% |
| FY22 | 6,559 | +3.9% | 5,609 | 950 | 14% | 376 | n/a | 18% |
| FY23 | 7,082 | +8.0% | 6,453 | 629 | 9% | −186 | −1.41 | 0% |
| FY24 | 8,171 | +15.4% | 6,974 | 1,197 | 15% | 18 | 0.13 | 82% |
| FY25 | 9,151 | +12.0% | 7,706 | 1,445 | 16% | 91 | 0.69 | 20% |
| FY26 | 8,869 | −3.1% | 7,947 | 922 | 10% | −326 | −2.45 | 0% |
3.2 Profitability Ratios — Compounded Growth
| Metric | 10Y | 5Y | 3Y | TTM |
|---|
| Sales Growth | n/a | 7% | 8% | −3% |
| Profit Growth | n/a | n/m | −24% | −429% |
| Stock Price CAGR | n/a | n/a | +22% | −19% (1Y) |
| Return on Equity | n/a | 0% | −1% | −4% (Last Year) |
3.3 Working Capital & Efficiency Ratios
| Ratio | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | 5Y Δ |
|---|
| Debtor Days | 91 | 99 | 93 | 95 | 94 | 89 | −2 |
| Inventory Days | 218 | 207 | 227 | 269 | 261 | 345 | +127 |
| Days Payable | 163 | 153 | 161 | 190 | 173 | 279 | +116 |
| Cash Conversion Cycle | 147 | 153 | 159 | 174 | 182 | 155 | +8 |
| Working Capital Days | 44 | 36 | 13 | 21 | 60 | 50 | +6 |
| ROCE % | n/a | 7% | 2% | 5% | 6% | 3% | −4 pp |
3.4 Balance Sheet Evolution (₹ Cr)
| Line Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | CAGR |
|---|
| Equity Capital | 995 | 1,186 | 1,193 | 1,323 | 1,324 | 1,327 | +6% |
| Reserves | 4,610 | 5,511 | 5,580 | 6,588 | 6,801 | 6,835 | +8% |
| Borrowings | 3,025 | 4,128 | 5,637 | 4,710 | 4,856 | 5,675 | +13% |
| Other Liabilities | 2,047 | 1,781 | 1,893 | 2,461 | 2,447 | 4,128 | +15% |
| Total Liabilities | 10,677 | 12,605 | 14,303 | 15,083 | 15,429 | 17,965 | +11% |
| Fixed Assets | 6,105 | 6,879 | 7,469 | 7,990 | 8,133 | 8,985 | +8% |
| CWIP | 627 | 1,172 | 1,419 | 1,116 | 977 | 799 | +5% |
| Investments | 123 | 267 | 639 | 385 | 291 | 437 | +29% |
| Other Assets | 3,822 | 4,286 | 4,777 | 5,592 | 6,028 | 7,744 | +15% |
| Total Assets | 10,677 | 12,605 | 14,303 | 15,083 | 15,429 | 17,965 | +11% |
3.5 Cash Flow Statement Trends (₹ Cr)
| Cash Flow Component | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | Trend |
|---|
| Cash from Operating Activity | 598 | 766 | 484 | 1,005 | 892 | 1,653 | ↑ 2.8x |
| Cash from Investing Activity | −4,464 | −1,737 | −1,334 | −416 | −488 | −826 | ↓ moderating |
| Cash from Financing Activity | 3,977 | 794 | 818 | −422 | −441 | −39 | ↓ deleveraging |
| Net Cash Flow | 110 | −177 | −32 | 166 | −37 | 788 | ↑ strong FY26 |
| Free Cash Flow | −5 | −91 | −461 | 294 | 233 | 776 | ↑↑ 3.3x jump |
| CFO/OP Ratio | 52% | 98% | 107% | 97% | 85% | 202% | ↑↑ best in 5Y |
3.6 Five-Year Financial Health Scorecard
| Financial Health Metric | FY21 | FY26 | Verdict |
|---|
| Sales Growth (5Y CAGR) | — | +7.0% | Mediocre |
| OPM Compression | 23% | 10% | Negative |
| Net Debt/Equity | ~0.4x | ~0.64x | Manageable |
| FCF Generation | −₹5 Cr | +₹776 Cr | Strongly Positive |
| CWIP Normalization | ₹627 Cr | ₹799 Cr | Capex peaking |
| Promoter Holding | 34.78% | 34.85% | Stable |
| CFO/OP Quality | 52% | 202% | Excellent |
| Working Capital Days | 44 | 50 | Stable |
| Inventory Days | 218 | 345 | WATCH — buildup |
| ROCE Trend | n/a | 3% | Sub-cost-of-capital |
§4 — Industry & Competition: Pharma + CDMO Peer Comparison
PPL operates in two interlocking industries — the global CDMO market (estimated at $160–180 Bn in 2026, growing at 8–10% CAGR) and the Indian hospital generics market (estimated at $2.5 Bn in 2026, growing at 12–14% CAGR). The CDMO industry is in a post-destocking recovery cycle with biopharma R&D budgets stabilizing after the 2022–24 venture capital pullback, and the complex injectable generics market is benefiting from US drug shortages driving import dependency.
4.1 Indian Pharma + CDMO Peer Set
| Company | Ticker | Mkt Cap (₹ Cr) | FY26 Sales (₹ Cr) | FY26 OPM % | FY26 ROE % | Core Focus |
|---|
| Piramal Pharma | PPLPHARMA | 21,821 | 8,869 | 10% | −4% | CDMO + Complex Injectables + OTC |
| Sun Pharma | SUNPHARMA | ~3,80,000 | ~52,000 | ~26% | ~15% | Specialty + Branded Generics + API |
| Cipla | CIPLA | ~1,20,000 | ~28,000 | ~22% | ~14% | Respiratory + HIV + API |
| Laurus Labs | LAURUS | ~32,000 | ~6,200 | ~19% | ~10% | API + CDMO + Specialty FDF |
| Divi's Labs | DIVIS | ~1,50,000 | ~9,800 | ~30% | ~14% | API + Custom Synthesis |
| Sai Life Sciences | SAILIFE | ~22,000 | ~3,800 | ~20% | ~12% | CRDMO pure-play |
| Syngene | SYNGENE | ~35,000 | ~9,000 | ~26% | ~14% | CRDMO pure-play (Biocon) |
| Suven Pharma | SUVENPHAR | ~15,000 | ~2,500 | ~30% | ~18% | CDMO pure-play |
4.2 Peer Profitability Comparison (FY26)
| Metric | PPL | SUNPHARMA | CIPLA | LAURUS | DIVIS | Syngene | Suven |
|---|
| Sales Growth (5Y CAGR) | +7% | +12% | +9% | +18% | +15% | +15% | +20% |
| FY26 OPM | 10% | ~26% | ~22% | ~19% | ~30% | ~26% | ~30% |
| FY26 ROE | −4% | ~15% | ~14% | ~10% | ~14% | ~14% | ~18% |
| Net Debt/Equity | ~0.6x | <0.1x | <0.1x | ~0.4x | <0.1x | ~0.2x | ~0.2x |
| Working Capital Days | 50 | ~80 | ~75 | ~120 | ~140 | ~100 | ~110 |
| FCF/Sales % | +8.7% | +12% | +10% | +5% | +15% | +8% | +12% |
| CFO/EBITDA | 202% | ~85% | ~90% | ~70% | ~85% | ~80% | ~90% |
4.3 CDMO Market Segmentation (Global, 2026E)
| Sub-segment | Market Size (USD Bn) | Growth | PPL Exposure |
|---|
| Small Molecule API | ~75 | ~6% | High |
| Drug Product (Oral Solid) | ~40 | ~8% | Medium |
| Sterile Injectables | ~25 | ~12% | High (CHG + CDMO) |
| High-Potency API (HPAPI) | ~15 | ~14% | High (Lexington) |
| Antibody-Drug Conjugates (ADC) | ~10 | ~20% | High (Aurora, Morpeth) |
| Biologics / Cell Culture | ~25 | ~10% | Medium (Boston DSO) |
| Total Addressable | ~190 | ~8–10% | ~10% share |
4.4 Competitive Positioning Matrix
| Competitive Vector | PPL Strength | PPL Weakness | Threat |
|---|
| Scale | Top-10 global CDMO | Smaller than Lonza, Catalent | Lonza, Samsung Biologics |
| High-Potency | Top-3 globally | Limited commercial mfg | Cambrex, Carbogen Amcis |
| ADC | Aurora site (leading) | Capacity-constrained | Catalent, Lonza, Piramal |
| Sterile Injectables | Indore plant (large) | 2019 FDA issues | Hospira, B. Braun |
| API Cost Position | India-based (low cost) | Higher debt than peers | Aurobindo, Laurus, Divis |
| R&D Capability | 6,500+ scientists | Lower than Syngene | Syngene, Suven |
| Debt/Equity | 0.64x | Higher than peer median | All listed peers |
| Working Capital Efficiency | 50 days | Better than API peers | Laurus, Divis (worse) |
4.5 Indian Hospital Injectables Market
| Therapy Area | Market Size (₹ Cr, 2026E) | Growth | PPL Position |
|---|
| Anesthesia (Propofol, Lignocaine) | ~2,500 | +10% | Top-2 (PPS + CHG) |
| Anti-Infectives (Meropenem, Colistin) | ~3,200 | +8% | Top-3 |
| Pain Management (Bupivacaine, Fentanyl) | ~1,200 | +12% | Top-5 |
| Contrast Media (Iohexol, Gadolinium) | ~1,800 | +15% | Mid-tier |
| Electrolytes & Nutrition | ~2,000 | +11% | Top-5 |
| Total Indian Hospital Injectables | ~10,700 | +11% | ~8–10% share |
4.6 USFDA & Regulatory Backdrop
| PPL Site | Last FDA Inspection | Outcome | Status |
|---|
| Lexington KY (Mallinckrodt legacy) | 2023 | VAI (Voluntary Action Indicated) | Operational |
| Aurora Canada (Mallinckrodt) | 2024 | Health Canada + USFDA — clear | Operational |
| Morpeth UK | 2024 (MHRA) | Clear | Operational |
| Indore (CHG Sterile) | 2022 | OAI (now reclassified) | Resolved |
| Bethlehem PA (CDMO) | 2023 | VAI | Operational |
| Visakhapatnam (API) | 2024 | Clear | Operational |
| Pithampur (CHG) | 2023 | Clear | Operational |
4.7 Industry Tailwinds & Headwinds
| Tailwinds | Headwinds |
|---|
| +12% US complex injectable shortages | −5% global biopharma R&D budgets |
| +20% ADC market growth | −10% CDMO pricing in destocking cycle |
| India PLI scheme for API | +100 bps interest cost headwind |
| Reshoring of US pharma supply | Geopolitical export curbs (China API) |
| GLP-1/Obesity drug boom (CDMO) | Fertility rate decline (long-term) |
| Hatch-Waxman reform discussions | Drug pricing legislation (IRA) |
§5 — DCF Valuation: Sum-of-the-Parts (SOTP)
PPL is best valued on an SOTP basis because its three segments — PPS (CDMO), CHG (Hospital Generics), and ICH (Consumer Healthcare) — have fundamentally different growth, margin, and capital intensity profiles. A single blended multiple masks value. We apply EV/EBITDA for PPS (global CDMO comp), P/E for CHG (generics comp), and P/E for ICH (FMCG comp), then bridge to equity value by subtracting net debt and adding cash/investments.
5.1 SOTP Build (₹ Cr unless noted)
| Segment | Methodology | FY27E EBITDA/NI (₹ Cr) | Multiple | Implied Value (₹ Cr) | % of EV |
|---|
| PPS (CDMO) | EV/EBITDA | ~1,400 | 18x | 25,200 | 70% |
| CHG (Hospital Generics) | P/E | ~250 | 25x | 6,250 | 17% |
| ICH (Consumer Healthcare) | P/E | ~180 | 30x | 5,400 | 15% |
| Enterprise Value | — | — | — | ~36,850 | 100% |
| (−) Net Debt FY26 | — | — | — | 5,238 | — |
| (+) Cash & Investments | — | — | — | 437 | — |
| (+) Minority adj | — | — | — | 0 | — |
| Equity Value | — | — | — | ~32,049 | — |
| Diluted Shares (Cr) | — | — | — | ~164.5 | — |
| Implied Fair Value (₹/share) | — | — | — | ~₹195 | — |
| CMP (₹) | — | — | — | 164 | — |
| Upside (%) | — | — | — | +19% | — |
5.2 PPS (CDMO) Valuation Cross-Check
| Method | Multiple | Implied EV/EBITDA | Comment |
|---|
| Global CDMO Peers (Syngene, Suven) | 20–22x | ~21x | Higher end of range |
| API Peers (Laurus, Divis) | 15–18x | ~16x | Lower end — too punitive for ADC capability |
| Lonza, Catalent, Samsung Bio | 18–24x | ~21x | Our 18x assumes India-discount |
| Weighted Average (Our View) | — | 18x | Captures India discount + debt |
5.3 CHG (Hospital Generics) Valuation Cross-Check
| Method | Multiple | Comment |
|---|
| Aurobindo, Gland, Hospira | 20–28x | Median 25x |
| Stress test (low growth) | 18x | For bear case |
| Stress test (high growth) | 30x | For bull case |
| Our Estimate | 25x | Mid-point |
5.4 ICH (Consumer Healthcare) Valuation Cross-Check
| Method | Multiple | Comment |
|---|
| Dabur, Marico, Emami (FMCG) | 35–45x | Premium for brand |
| Pharma OTC (Cipla Health, Mankind) | 25–32x | Closer comp |
| Our Estimate | 30x | Discount for scale |
5.5 DCF Sensitivity (PPS Only, EV)
| WACC ↓ / Terminal Growth → | 3% | 4% | 5% | 6% |
|---|
| 9% | 22,500 | 24,800 | 27,600 | 31,200 |
| 10% | 20,800 | 22,800 | 25,000 | 27,800 |
| 11% | 19,400 | 21,000 | 22,800 | 25,200 |
| 12% | 18,100 | 19,500 | 21,000 | 23,000 |
5.6 Bear / Base / Bull Scenarios
| Scenario | Probability | Fair Value (₹) | Upside/Downside | Trigger |
|---|
| Bear | 25% | 130 | −21% | CDMO recovery delayed, debt up |
| Base | 55% | 195 | +19% | SOTP normalizes, FCF sustains |
| Bull | 20% | 270 | +65% | ADC capacity unlocked, FDA clear |
| Probability-weighted FV | — | ~₹195 | +19% | Blended fair value |
5.7 Valuation Multiples vs Peers (FY27E)
| Company | P/E (FY27E) | EV/EBITDA (FY27E) | P/B | ROE % |
|---|
| Piramal Pharma | ~32x (normalised) | 18x | 2.7x | ~6% (FY27E) |
| Sun Pharma | ~28x | ~18x | ~4.5x | ~15% |
| Cipla | ~22x | ~13x | ~3.0x | ~14% |
| Laurus Labs | ~30x | ~16x | ~4.0x | ~12% |
| Divi's Labs | ~45x | ~28x | ~6.0x | ~15% |
| Syngene | ~35x | ~20x | ~5.0x | ~15% |
| Suven Pharma | ~30x | ~18x | ~4.5x | ~18% |
5.8 Key Valuation Risks
| Risk | Impact on FV |
|---|
| CDMO volume miss | −₹30/share |
| Higher-than-expected capex | −₹15/share |
| FDA OAI at any plant | −₹25/share |
| Forex loss (USD/INR) | −₹10/share |
| ADC contract win (large) | +₹20/share |
| Cost optimization + 200 bps OPM | +₹30/share |
§6 — Analyst Consensus
Sell-side coverage on PPL is moderate — approximately 12–14 analysts track the stock, including BofA, Morgan Stanley, Jefferies, CLSA, Nomura, Macquarie, Motilal Oswal, Axis Capital, Antique, Prabhudas Lilladher, Dolat Capital, and YES Securities. Consensus rating skews neutral-to-cautiously bullish post FY26 results, with a 12-month target price range of ₹150–₹240 and a median of ₹195, closely matching our SOTP-derived fair value.
6.1 Brokerage Rating Distribution
| Rating | # of Analysts | % of Coverage |
|---|
| Strong Buy | 1 | 8% |
| Buy | 4 | 31% |
| Hold | 5 | 38% |
| Underperform/Sell | 3 | 23% |
| Total Coverage | 13 | 100% |
6.2 Target Price Range
| Metric | Value (₹) | Note |
|---|
| Highest Target | 240 | Antique / BofA (bull case) |
| Median Target | 195 | In line with our SOTP |
| Mean Target | 192 | Skewed slightly to upside |
| Lowest Target | 150 | Jefferies (bear case) |
| CMP | 164 | — |
| Implied Upside (Median) | +19% | — |
6.3 Recent Brokerage Actions (Last 6 Months)
| Date | Broker | Action | Target (₹) | Thesis |
|---|
| Apr 2026 | BofA Securities | Upgrade to Buy | 220 | CDMO recovery confirmed |
| May 2026 | Jefferies | Maintain Underperform | 150 | Debt-funded capex risk |
| May 2026 | CLSA | Maintain Hold | 190 | Valuation fair; catalyst needed |
| May 2026 | Motilal Oswal | Maintain Buy | 215 | FCF inflection story |
| Apr 2026 | Axis Capital | Maintain Hold | 185 | CHG segment under pressure |
| Apr 2026 | Antique Stock | Maintain Buy | 240 | Best-in-class CDMO infra |
| Mar 2026 | Nomura | Maintain Hold | 180 | In line with our view |
| Mar 2026 | Prabhudas Lilladher | Maintain Hold | 195 | SOTP-derived |
6.4 Consensus Earnings Forecasts
| Metric | FY27E | FY28E | FY29E |
|---|
| Sales Consensus (₹ Cr) | 9,500–9,800 | 10,500–11,000 | 11,800–12,500 |
| EBITDA Consensus (₹ Cr) | 1,250–1,400 | 1,500–1,700 | 1,800–2,100 |
| OPM % | 13–14% | 14–16% | 15–17% |
| Net Profit (₹ Cr) | 200–350 | 400–600 | 700–900 |
| EPS Consensus (₹) | 1.2–2.1 | 2.4–3.6 | 4.2–5.5 |
6.5 Consensus Growth Assumptions
| Driver | FY27E | FY28E | FY29E |
|---|
| PPS CDMO Growth | +12–15% | +14–18% | +15–20% |
| CHG Growth | +8–10% | +10–12% | +12–14% |
| ICH Growth | +10–12% | +11–13% | +12–14% |
| Group Sales Growth | +8–10% | +10–12% | +12–14% |
| EBITDA Margin Expansion | +200–300 bps | +100–200 bps | +100–150 bps |
6.6 Where We Differ From Consensus
| Topic | Consensus View | Our View | Reason |
|---|
| FY27E OPM | 13–14% | 15% | Inventory destocking ended |
| FY27E Net Profit | +₹275 Cr avg. | +₹400 Cr | Other income normalizes |
| Net Debt by FY28 | Stable ~₹5,000 Cr | Down to ~₹4,000 Cr | FCF used for deleveraging |
| Capex Intensity | ₹600–800 Cr/yr | ₹500–700 Cr/yr | CWIP normalizes |
| Target Price | ₹192 avg. | ₹195 | Slightly more bullish on PPS |
| Rating | Mostly Hold/Buy | Neutral (initiating) | Weigh debt + execution risk |
§7 — Shareholding Pattern: Piramal Group Anchor
Piramal Group holds 34.85% of PPL as the promoter anchor, providing governance stability and strategic continuity but limiting free-float-driven price discovery. FIIs at 30.17% and DIIs at 15.61% together control ~46% — a high institutional share that supports liquidity but also creates crowding-out risk in stressed scenarios. Public shareholding at 19.01% is a relatively thin free float for a company of this size, and the shareholder count has nearly doubled from 2,41,359 (Mar 2023) to 4,50,661 (Mar 2026), reflecting broadening retail participation post-demerger.
7.1 Shareholding Trend (Quarterly, %)
| Quarter | Promoters | FIIs | DIIs | Public | Others |
|---|
| Jun 2023 | 34.78% | 35.01% | 5.48% | 24.32% | 0.39% |
| Sep 2023 | 35.02% | 32.37% | 8.01% | 24.21% | 0.38% |
| Dec 2023 | 35.02% | 32.51% | 9.68% | 22.41% | 0.38% |
| Mar 2024 | 35.02% | 30.58% | 12.12% | 21.89% | 0.37% |
| Jun 2024 | 34.94% | 31.41% | 12.95% | 20.20% | 0.47% |
| Sep 2024 | 34.94% | 31.73% | 13.80% | 19.06% | 0.45% |
| Dec 2024 | 34.94% | 31.68% | 14.09% | 18.85% | 0.40% |
| Mar 2025 | 34.94% | 31.49% | 14.78% | 18.42% | 0.34% |
| Jun 2025 | 34.85% | 30.86% | 14.25% | 19.46% | 0.57% |
| Sep 2025 | 34.85% | 30.27% | 14.89% | 19.46% | 0.51% |
| Dec 2025 | 34.85% | 29.66% | 15.68% | 19.35% | 0.44% |
| Mar 2026 | 34.85% | 30.17% | 15.61% | 19.01% | 0.34% |
7.2 Annual Shareholding (Mar Year-End, %)
| Year | Promoters | FIIs | DIIs | Public | Others |
|---|
| Mar 2023 | 34.78% | 39.28% | 4.98% | 20.57% | 0.39% |
| Mar 2024 | 35.02% | 30.58% | 12.12% | 21.89% | 0.37% |
| Mar 2025 | 34.94% | 31.49% | 14.78% | 18.42% | 0.34% |
| Mar 2026 | 34.85% | 30.17% | 15.61% | 19.01% | 0.34% |
7.3 Shareholder Count Evolution
| Quarter | No. of Shareholders | YoY Change |
|---|
| Mar 2023 | 2,41,359 | Base |
| Jun 2023 | 2,77,270 | +14.9% |
| Sep 2023 | 3,00,606 | +24.5% |
| Dec 2023 | 2,92,312 | +21.1% |
| Mar 2024 | 2,97,996 | +23.5% |
| Jun 2024 | 3,06,398 | +10.5% |
| Sep 2024 | 3,59,751 | +19.7% |
| Dec 2024 | 4,18,442 | +43.1% |
| Mar 2025 | 4,32,843 | +45.2% |
| Jun 2025 | 4,58,430 | +49.6% |
| Sep 2025 | 4,62,511 | +28.6% |
| Dec 2025 | 4,53,830 | +8.4% |
| Mar 2026 | 4,50,661 | +4.1% |
7.4 Top Likely Institutional Holders (Inference, not confirmed)
| Likely Holder Type | Estimated Stake | Profile |
|---|
| Piramal Group (Promoter) | 34.85% | Ajay Piramal + family |
| Foreign Portfolio Investors (FPIs) | ~30% | Likely include BlackRock, Vanguard, Norges Bank, GIC, ADIA |
| Domestic Mutual Funds | ~12% | SBI MF, ICICI Pru, HDFC, Nippon, Kotak, Axis |
| Insurance Companies (LIC + Pvt) | ~3% | Long-term holders |
| EPF / NPS | ~1% | Index inclusion beneficiaries |
| Retail / HNI Public | ~19% | Growing base — 4.5L+ holders |
7.5 Key Shareholding Observations
| Observation | Implication |
|---|
| Promoter stake stable at 34.85% | No pledge risk; aligned with minorities |
| FIIs steady at 30% (post-Mar 2023 demerger) | Global pharma appeal holding |
| DIIs doubled from 5% to 15% | Domestic institutions accumulating |
| Shareholders nearly doubled in 3 years | Strong retail interest |
| Public (retail) share falling | Migration to DII/FII |
| No bulk-deal/block-deal history | Stable ownership structure |
| Entity | Relationship | Exposure |
|---|
| Piramal Finance (NBFC) | Group company | PPL may have ICDs/loans to PF — disclosed in notes |
| Piramal Glass (now merged with PPL ops) | Group supplier | Captive — internal pricing |
| Piramal Capital & Housing Finance | Group NBFC | Loans to PPL at arms-length rates |
| Piramal Foundation (CSR) | Group trust | CSR spend tracked |
| Nandini Piramal (Chair) | Promoter family | No direct PPL share dealings |
| Ajay Piramal (Chairman) | Promoter | No recent open-market sales |
7.7 Pledge Status & Insider Activity
| Parameter | Status |
|---|
| Promoter Shares Pledged | 0% (no pledge) |
| Insider Trades Last 6M | None material reported |
| SAST Disclosures | Compliant |
| Insider Trading Plan | No open window |
| Open Offer History | None post-listing |
§8 — Key Risks: CDMO Pipeline & Balance Sheet
PPL carries a unique risk profile that is fundamentally different from generic pharma peers — heavy CDMO client concentration, capex-cycle execution risk, debt servicing, and FDA-compliance exposure across multiple jurisdictions. We frame the top 10 risks with probability × impact scoring and mitigants.
8.1 Risk Matrix
| # | Risk | Probability | Impact | Score | Mitigant |
|---|
| 1 | CDMO client concentration (top 5 = ~40% revenue) | High | High | 9 | Diversification into ADC, biologics |
| 2 | Debt servicing (₹5,675 Cr borrowings) | Medium | High | 8 | FCF improvement; refinancing |
| 3 | FDA OAI / Form 483 at any site | Medium | High | 8 | Quality system upgrades ongoing |
| 4 | US drug pricing (IRA, IRA-Medicare) | High | Medium | 7 | CDMO less exposed than branded |
| 5 | CDMO biopharma funding cycle (biotech VC) | Medium | Medium | 6 | Diversified client base |
| 6 | Capex over-runs (Boston DSO site) | Medium | Medium | 6 | CWIP normalizing |
| 7 | Forex (USD/INR, EUR/INR) | High | Low | 5 | Hedging program in place |
| 8 | Litigation (product liability, IP) | Low | High | 5 | Insurance + indemnities |
| 9 | Key personnel attrition | Medium | Low | 4 | ESOP, retention bonuses |
| 10 | Geopolitical (China API disruption) | Low | Medium | 4 | Reshoring tailwind |
8.2 CDMO Pipeline & Client Risk
| CDMO Risk | Detail | Mitigant |
|---|
| Top client concentration | ~10–15% revenue from single largest | Multi-year agreements, pipeline diversification |
| Project cancellations | ~15–20% of CDMO projects cancelled mid-cycle | Book-and-bill pricing model |
| Capacity utilization | Sites at 60–70% utilization | Long lead pipeline build |
| Inventory destocking | 5-quarter cycle (FY25 Q3 to FY26 Q2) | Normalizing in FY26 Q4 |
| ADC competition | Lonza, Catalent, Samsung Bio | Aurora site advantage |
| Sterile injectable capacity | Industry capacity tight | Indore plant is top-3 in India |
| HPAPI competition | Cambrex, Carbogen | Lexington site heritage |
8.3 Debt & Liquidity Risk Detail
| Debt Component | FY26 (₹ Cr) | Comment |
|---|
| Long-term Borrowings | ~4,500 | Rupee + USD denominated |
| Short-term Borrowings | ~1,175 | Working capital |
| Total Borrowings | 5,675 | +₹819 Cr YoY |
| Less: Cash & Equivalents | ~437 | Low cash buffer |
| Net Debt | ~5,238 | ~0.64x equity |
| Interest Cost (FY26) | 341 | 6% effective rate |
| EBITDA / Interest Coverage | ~2.7x | Tight but adequate |
| Debt Maturity Profile | Bullet 2027–2030 | Refinancing risk 2027 |
8.4 CDMO Operational Risk
| Risk | Detail | Mitigant |
|---|
| Yield variability | API yield drives CDMO margins | Process R&D investment |
| Technology transfer failures | Site-to-site project handoffs | Dedicated PMO team |
| Schedule slippage | Late delivery = penalty clauses | Project management tools |
| Quality deviations | OOS results, batch failures | QA/QC investment |
| Environmental, Health, Safety | Multi-site, multi-jurisdiction | EHS audit program |
| Cybersecurity (manufacturing) | Ransomware on pharma rising | SOC, network segmentation |
| Supply chain disruption | KSM/API availability | Multi-sourcing |
8.5 India-Specific Risks
| Risk | Detail | Mitigant |
|---|
| GST/Customs policy | Pharma under lens | PLI scheme benefits |
| Rupee depreciation | Pos: export revenue, Neg: imported KSM | Natural hedge |
| India PLI scheme renewal | 2028 expiry | Lobbying + compliance |
| State-level issues (Maharashtra, MP) | Plant location concentration | Multi-state presence |
| Wage inflation (India) | ~7–9% annual | Automation investment |
8.6 ESG Risk Snapshot
| ESG Factor | Status | Trend |
|---|
| E (Environmental) | Mid-pack | Improving (CDP, sustainability reports) |
| S (Social — drug access, pricing) | Strong (generics) | Stable |
| G (Governance) | Mid-pack | Stable — Piramal Group discipline |
| BRSR Compliance | Yes | Disclosed in annual report |
| SBTi / Net Zero Target | Committed by 2030 | On track |
8.7 Cyber & IT Risk
| Risk Vector | Mitigation |
|---|
| Ransomware | Endpoint protection + immutable backups |
| Data breach (PHI/PII) | Encryption + DLP |
| IP theft (CDMO client data) | Network segmentation + access control |
| OT/IT convergence | Purdue model implementation |
| Third-party SaaS risk | Vendor risk management |
§9 — Investment Thesis
We initiate coverage of Piramal Pharma with a Neutral rating and a 12-month fair value of ₹195/share (~+19% upside from CMP of ₹164). The thesis is a barbell: a high-quality global CDMO franchise with structural tailwinds stapled to a cyclically depressed complex injectables business and a balance sheet still in deleveraging mode. Catalysts are visible — Q4 FY26 OPM recovery to 16.74% confirms CDMO destocking is over, FCF inflection to ₹776 Cr is a structural improvement, and CWIP normalization to ₹799 Cr means capex is past peak. However, valuation is fairly demanding at 2.69x book and 18x EV/EBITDA on FY27E for a −4% ROE business, and the +19% upside is not attractive enough to warrant a Buy in a market that pays for cleaner, more profitable pharma franchises (Sun Pharma, Divis, Syngene).
9.1 The Three Pillars of the Thesis
| Pillar | Bull Case | Bear Case | Our View |
|---|
| CDMO franchise | Top-3 globally in HPAPI/ADC; secular growth | Destocking cycles repeat; pricing pressure | Net positive — quality asset |
| Balance sheet | FCF funds deleveraging | Debt traps PPL in capex | Slowly improving |
| Earnings power | FY28-29 ₹600–900 Cr NP achievable | CDMO margin never returns | Recovery in FY27-28 |
9.2 Why Neutral, Not Sell
| Reason | Detail |
|---|
| CDMO recovery confirmed | Q4 FY26 OPM 16.74% — strong signal |
| FCF inflection | ₹776 Cr (FY26) vs ₹233 Cr (FY25) — 3.3x jump |
| Capex past peak | CWIP ₹799 Cr (FY26) vs ₹1,419 Cr (FY23) — −44% |
| SOTP fair value ₹195 | +19% upside is reasonable |
| Quality assets | Morpeth, Lexington, Aurora, Boston DSO |
| Piramal Group anchor | 34.85% promoter — no pledge |
9.3 Why Neutral, Not Buy
| Reason | Detail |
|---|
| FY26 net loss of ₹326 Cr | Worst year in 5 |
| ROE at −4% | Below cost of capital |
| Net debt up to ₹5,238 Cr | +₹819 Cr YoY |
| FY26 OPM 10% | Below FY21 23% |
| 3Y profit CAGR −24% | Destruction of value |
| Peer ROE 12–18% | PPL is subscale in profitability |
| Inventory days 345 | Watch for write-downs |
9.4 The Bull Case (₹270, ~+65% upside)
| Bull Catalyst | Probability | Timeframe |
|---|
| Large ADC contract win | Medium | 12–18M |
| CHG FDA approval for new sterile site | Medium | 6–12M |
| FCF crosses ₹1,500 Cr | Medium | FY28 |
| Net debt falls below ₹3,000 Cr | High | FY28–29 |
| OPM recovers to 18% | Medium | FY28 |
| GLP-1 contract bagged | Low–Medium | 12–24M |
9.5 The Bear Case (₹130, ~−21% downside)
| Bear Catalyst | Probability | Timeframe |
|---|
| FDA OAI at any plant | Low–Medium | 6–18M |
| CDMO destocking returns | Low | 12M+ |
| Net debt rises above ₹7,000 Cr | Low | FY27–28 |
| Inventory write-down | Low–Medium | Q1–Q2 FY27 |
| Promoter pledge (tail risk) | Very low | n/a |
| Forex loss (rupee appreciation) | Medium | Continuous |
9.6 Catalysts & Triggers (Next 6–12 Months)
| Catalyst | Date | Impact |
|---|
| Q1 FY27 results (Jun 2026) | Aug 2026 | Confirm OPM sustained >15% |
| FY27 guidance (mgmt commentary) | Aug 2026 | CDMO growth, OPM path |
| FDA inspection results | Rolling | Bethlehem, Morpeth, Indore |
| Capex announcement FY27 | Aug 2026 | ₹500–700 Cr range |
| New CDMO contract win | Any time | +5–10% on price |
| Annual report disclosure | Aug 2026 | Related-party, segmental |
| Index inclusion event | Sep 2026 | MSCI EM, FTSE |
9.7 Who Should Buy?
| Investor Profile | Action |
|---|
| Long-term value investor (3–5Y) | Accumulate on dips below ₹150 |
| Income/Dividend investor | Skip — no dividend track record |
| CDMO sector pure-play | Syngene/Suven preferred for cleaner exposure |
| Cyclical recovery play | Suited — Q4 FY26 is the trough signal |
| ESG-focused | Hold — BRSR compliance good |
| Small-cap quality | Wait for ROE >10% (FY28) |
| Tactical (6M) | Neutral — limited upside |
| Strategic (3Y+) | Buy on weakness — CDMO + ICH are quality |
9.8 Monitoring Checklist (Quarterly)
| Metric | Trigger | Action |
|---|
| Quarterly OPM | <13% for 2 quarters | Re-rate downside to ₹150 |
| Quarterly OPM | >17% for 2 quarters | Re-rate upside to ₹230 |
| Net Debt / EBITDA | >2.5x | Concern — debt trap |
| FCF | <₹500 Cr for 2Y | Quality concern |
| FDA inspection | OAI at any site | Severe — exit signal |
| Promoter pledge | Any pledge | Severe — exit signal |
| Segment mix shift | CDMO >65% of revenue | Re-rating higher |
| Capex | >₹900 Cr/yr | FCF erosion |
9.9 Final Verdict
| Parameter | Our View |
|---|
| Rating | Neutral |
| Fair Value (12M) | ₹195 |
| CMP | ₹164 |
| Implied Upside | +19% |
| Risk-Reward | Slightly positive |
| Time Horizon | 12–18 months |
| Conviction | Medium (60%) |
| Best-in-class? | No — ROE too low |
| Quality asset? | Yes — CDMO franchise |
| Cyclical bottom? | Likely yes (Q4 FY26 signal) |
| Forced buyer? | No |
| Forced seller? | No |